Milnacipran May Benefit Juvenile Fibromyalgia Patients

Milnacipran May Benefit Juvenile Fibromyalgia Patients
Fibromyalgia generally affects adult women. However, juvenile fibromyalgia (JFM) is a disorder that affects up to 6% of children and adolescent patients. More girls than boys are affected by JFM, but the disease is all-around underdiagnosed and undertreated. There exist no approved medications for JFM. A laboratory from the Women's Health Research Program at the University of Cincinnati College of Medicine, in collaboration with the Fatigue Consultation Clinic and the Forest Research Institute, conducted two clinic trials investigating a possible new treatment for JFM. The team found that milnacipran may benefit patients with JFM, but future investigations are necessary to develop the therapeutic agent for regular clinical use. "The open-label findings provide preliminary evidence that milnacipran may improve symptoms of JFM, with a safety and tolerability profile that is consistent with the experience in adult fibromyalgia patients," wrote the authors in their study, "Preliminary Experience Using Milnacipran in Patients With Juvenile Fibromyalgi: Lessons From a Clinical Trial Program." The researchers cannot be definitive with their conclusions about safety and efficacy, as both clinical trials were terminated due to low enrollment. "Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia (MyFi)" was a Phase 2, randomized placebo-controlled trial that evaluated the safety, tolerability, efficacy, and pharmacokinetics of minacipran in 13- to 17-year-old patients with JFM. Only
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *